CalciMedica, Inc.   Report issue

For profit Phase 2
Founded: La Jolla CA United States (2006)
Status: Acquired by Graybug Vision (2022)

Organization Overview

First Clinical Trial
2018
NCT03401190
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

CalciMedica, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

cm4620 (5 trials)

cm-4620 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Pancreatitis (Phase 2)

Pneumonia (Phase 2)

Syndrome (Phase 2)

Systemic Inflammatory Response Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 2